Systemic Approach to Advanced Colon Cancer Mohamed Abdulla (M.D.) Ass. Prof. Clinical Oncology Kasr El-Aini School of Medicine Cairo University April,

Slides:

Advertisements

Similar presentations

Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.

Advertisements

Progress Against Pancreatic Cancer. 1970–1979 Progress Against Pancreatic Cancer 1970– s: Tobacco use found to cause pancreatic cancer.

Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.

Therapeutic Strategies in Adjuvant Therapy of Colon Cancer Mohamed Abdulla (M.D.) Prof. of Clinical Oncology, Kasr El-Aini School of Medicine, Cairo University.

Management of Acoustic Neuroma NEMROCK Experience Mohamed Abdulla (M.D.) Ass. Professor of Clinical Oncology Kasr El-Aini School of Medicine.

CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.

D. Haller, CRC Symposium, Oncology Spectrums, NYC Combination and Sequential Chemotherapy of Metastatic Colorectal Cancer Daniel G. Haller, MD.

Neuroendocrinal Tumors : A Case of Mistaken Identity. Mohamed Abdulla M.D. Professor of Clinical Oncology, Kasr El-Aini School of Medicine Cairo University.

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.

Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.

Paolo Marchetti Oncologia Medica Ospedale Sant’Andrea & IDI IRCCS Roma Higher drug costs and healthcare savings: a true conflict of interest 1 Oncology:

Todays Clinical Trials. Tomorrow’s Cures. Robert L. Comis, MD 1 National Coalition for Cancer Research “Cancer 101” Congressional Briefing 09/10/14.

Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.

GI-NEUROENDOCRINE TUMORS THERAPEUTIC APROACHES Chemotherapy: older and recent schemes Ilias Athanasiadis, MD Medical Oncologist Director of the Oncology.

Eric Van Cutsem Head, Digestive Oncology, University Hospital Gasthuisberg and Professor of Internal Medicine, University of Leuven, Belgium Published.

Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Clara Natoli, MD Professor of Medical Oncology University G. D ' Annunzio Chieti - Pescara Clara Natoli, MD Professor of Medical Oncology University G.

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology

Management of Recurrent and Advanced Tumours: When are Tumours Resectable, and Multidisciplinary Management Dr. Andrew McFadden Surgical Oncology.

Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts Jeffrey Meyerhardt,

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225,

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.

Pre-Operative Therapy for Borderline Resectable Pancreatic Cancer: The Potential Role of Chemotherapy Robert A. Wolff, M.D. Associate Professor of Medicine.

CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.

Adjuvant Therapy of Colon Cancer: Where are we now ? Leonard Saltz, MD Memorial Sloan Kettering Cancer Center New York, NY.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.

Pharmacogenetics of Irinotecan Clinical perspectives: utility of genotyping Mark J. Ratain, MD University of Chicago 11/3/04.

PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Unintended Consequences of Expensive Cancer Therapeutics—The.

What should patients with BRAF mutant melanoma receive as front line therapy? Antoni Ribas, M.D. Professor of Medicine Professor of Surgery Professor of.

Neutron radiation therapy for advanced thyroid cancers Tobias R. Chapman, MD, George E. Laramore, PhD, MD, Stephen R. Bowen, PhD, Peter F. Orio, DO, MS.

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy Fady F. Youssef, MS, Parag.

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial Susanne M.

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

Fig. 2. Atypical response to VEGF-targeted therapy in colon cancer

Systemic treatment for colorectal cancer

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Reviewer: Dr Scott Berry Date posted: June 21, 2007

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Volume 69, Issue 4, Pages (April 2016)

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Authors: David Cunningham et al Date posted: April 3, 2008

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

by Alex Aleshin, and Peter L. Greenberg

Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease,

Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center

Aminah Jatoi, MD, Dawn Aranguren, PA-C Journal of Thoracic Oncology

Targeted Therapies for Hepatocellular Carcinoma

Volume 9, Issue 8, Pages S14-S17 (August 2012)

1 Sunnybrook Odette Cancer Centre, University of Toronto, Canada

Use of diphenhydramine as an adjunctive sedative for colonoscopy in patients on chronic opioid therapy: a randomized controlled trial Salman Nusrat,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Gregory G. Ginsberg, MD Gastrointestinal Endoscopy

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Gastrointestinal Endoscopy

Clostridial aortitis and colon cancer

Aimery de Gramont Association between 3 year Disease Free Survival and Overall Survival delayed with improved survival after recurrence in patients receiving.

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

A Review of First-Line Treatment for Small-cell Lung Cancer

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Presentation transcript:

Systemic Approach to Advanced Colon Cancer Mohamed Abdulla (M.D.) Ass. Prof. Clinical Oncology Kasr El-Aini School of Medicine Cairo University April, 2005

Heterogeneous Groups of Patients Several Agents Different Schedules Pharmacogenomic Variations

Which Regimen to Be Used as a First Line ttt in Advanced or Metastatic Colon Cancer???

DON’T FORGET 5-Fu is no longer the only cytotoxic agent with clinical activity. Capecitabine is an effective alternative to infusional 5-Fu. Oxaliplatin & Irinotecan have nearly doubled the median survival. Oxaliplatin improves PFS. Initial validation of the promising systemic target therapies.

Highlights of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, Feb Seminars in Oncology; Volume 32, Number 1,

ANNOUNCEMENT